Merck

Merck

Yahoo Finance • 10 hours ago

Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips

Quick Read Moderna shed 7% of Tuesday's 14% Wolfe Research upgrade rally, while BioNTech's 2% dip confirms the selloff is Moderna-specific. IBB barely moved while Moderna's $59 billion cap prices in Merck's unapproved intismeran program a... Full story

Yahoo Finance • 12 hours ago

Merck Stock Hits New 52-Week High: What's Driving the Rally?

Shares of Merck MRK hit a fresh 52-week high yesterday on renewed investor confidence over the company's long-term growth prospects and recent positive developments surrounding its pipeline progress, regulatory approvals, as well as merger... Full story

Yahoo Finance • 12 hours ago

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) provides broad, low-cost exposure to the entire healthcare sector, whereas the VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a concentrated, higher-yielding focus on global pharmaceuti... Full story

Yahoo Finance • yesterday

Moderna’s Cancer Vaccine Gives Stock a New Growth Story. Will It Have a Happy Ending?

Moderna and Merck’s personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential. Continue Reading... Full story

Yahoo Finance • yesterday

Schwab SCHD draws $679M as dividend ETF climbs 2.39%

The Schwab U.S. Dividend Equity ETF (SCHD) pulled in $679.26 million over five trading days as its share price climbed 2.39%, TipRanks reported. Three of the fund's biggest holdings made news in the same stretch, adding fresh fuel to a mo... Full story

Yahoo Finance • yesterday

Moderna Stock Soars on Cancer Vaccine Breakthrough

This article first appeared on GuruFocus. Moderna (NASDAQ:MRNA) shares climbed nearly 13% on Tuesday as investors weighed new analyst support following encouraging results from the company's late-stage cancer program. The move came after... Full story

Yahoo Finance • yesterday

Moderna, Nvidia, Apple, Dick’s, Robinhood, AMD, and More Stocks That Explain Today’s Market

Stocks were modestly higher Tuesday as Wall Street traded cautiously ahead of Nvidia earnings on Wednesday. Moderna gained 14% to $157.92 and was the best-performing stock in the Wolfe Research upgraded the stock to Peer Perform from Un... Full story

Yahoo Finance • yesterday

How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?

AbbVie's ABBV oncology franchise continued to face pressure in the second quarter of 2026, primarily due to the ongoing decline in sales of the blood cancer drug Imbruvica. The company generated oncology revenues of $1.65 billion in the qu... Full story

Yahoo Finance • yesterday

Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

Immunocore's IMCR sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM), has been witnessing strong demand. Currently, the company's top line solely co... Full story

Yahoo Finance • yesterday

Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name?

Quick Read Moderna surged 11% while BioNTech gained just 2% on no catalyst, with MRNA's Reddit sentiment score of 88 flagging crowded retail positioning over fundamentals. BioNTech trails XBI's 3% session gain and its 35% YTD return, whil... Full story

Yahoo Finance • yesterday

Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Merck & Co., Inc. (NYSE:MRK) jumped 12.6% to a record $152.20 on August 19 after a pivotal melanoma trial validated intismeran autogene, the individualized mRNA cancer therapy developed with Moderna. In the 1,137-patient Phase 3 INTerpath-... Full story

Yahoo Finance • yesterday

“Give Me Anything But Tech”: Jim Cramer’s Bold Call on the Market’s Next Big Rotation

Quick Read NOW and CRM surged 30% and 28% in a month as money rotates out of data center plays into software on constrained AI infrastructure. MRNA exploded 115% in one week on melanoma vaccine data showing a 49% reduction in recurrence r... Full story

Yahoo Finance • 2 days ago

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.

Quick Read MRK and MRNA's intismeran autogene beat Keytruda alone on recurrence-free survival in Phase 3 melanoma, though no specific efficacy numbers have been released yet. BNTX surged 21% on read-across excitement, while ILMN rose 16%... Full story

Yahoo Finance • 2 days ago

Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax

Positive topline results from Phase 3 trial of personalized cancer vaccine for melanoma de-risk LNP-mRNA therapies such as CancerVax Lehi, Utah, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal... Full story

Yahoo Finance • 2 days ago

Analysts See Drastic Change For This Particular Part Of Healthcare

The biotech fund is one of two ETFs in IBD Leaderboard. The S&P 500 Biotech index gapped up to nearly an all-time high last Wednesday, a bullish day for the industry. While Moderna shares have remained volatile since then — down 23.5% Th... Full story

Yahoo Finance • 2 days ago

Personalis falls amid a downgrade as a competitive bid appears unlikely

[Blood test sample for Tumor markers test for diagnosis cancer] angelp Personalis Inc. (PSNL [https://seekingalpha.com/symbol/PSNL]) dropped 6% amid a downgrade at Craig-Hallum to hold from buy as the cancer test maker is unlikely to see... Full story

Yahoo Finance • 2 days ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 days ago

Should You Buy Moderna Stock Following Its Cancer Breakthrough?

Moderna MRNA has gained renewed investor attention after its personalized mRNA-based cancer therapy delivered positive results in a late-stage study. The therapy has been developed in collaboration with Merck MRK. Moderna's Cancer Therapy... Full story

Yahoo Finance • 2 days ago

Eli Lilly Has a $100 Billion Revenue Story in the Making, 18% Upside Ahead

Quick Read LLY carries a BUY rating and $1,480 price target as $87 billion FY2026 guidance puts a $100 billion revenue milestone within reach. NVO trades at $156 billion, which is one-seventh of LLY's market cap despite a comparable GLP-1... Full story

Yahoo Finance • 2 days ago

Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips

Quick Read MRNA drops 7% to $135 after a 392% YTD surge, as traders book profits with no new negative catalysts driving the decline. Partner MRK gained 47% YTD on Keytruda's label expansion potential, while BNTX trails at 22% amid a slowe... Full story